Table 1 Socio-demographic and tumour characteristics associated with use of adjuvant chemotherapya
Use of chemotherapy | |||||
|---|---|---|---|---|---|
Characteristic | Total population (N = 1212) | Total chemotherapy (N = 1212) | NZ European (N = 924) | Māori (N = 218) | |
n (%) | n (%)b | p | n (%)b | n (%)b | |
Overall | 1212 (100) | 836 (69.0) | 635 (68.7) | 149 (68.3) | |
Age (yrs.) | <0.001 | ||||
< 40 | 100 (8.3) | 90 (90.0) | 58 (89.2) | 18 (90.0) | |
40-49 | 338 (27.9) | 276 (81.7) | 200 (81.3) | 56 (81.2) | |
50-59 | 434 (35.8) | 309 (71.2) | 245 (72.5) | 53 (68.8) | |
60-69 | 340 (28.1) | 161 (47.4) | 132 (48.0) | 22 (42.3) | |
Deprivation | 0.402 | ||||
Dep 1-2 | 139 (11.5) | 100 (71.9) | 88 (71.5) | 8 (80.0) | |
Dep 3-4 | 126 (10.4) | 89 (70.6) | 72 (70.6) | 12 (75.0) | |
Dep 5-6 | 313 (25.8) | 216 (69.0) | 174 (67.7) | 29 (70.7) | |
Dep 7-8 | 315 (26.0) | 213 (67.6) | 160 (67.8) | 39 (61.9) | |
Dep 9-10 | 319 (26.3) | 218 (68.3) | 141 (68.4) | 61 (69.3) | |
Surgical hospital type | 0.002 | ||||
Private | 406 (33.5) | 303 (74.6) | 271 (74.0) | 21 (80.8) | |
Public | 806 (66.5) | 533 (66.1) | 364 (65.2) | 128 (66.7) | |
Diagnostic type | 0.033 | ||||
Screen detected | 407 (33.6) | 235 (57.7) | 195 (57.9) | 30 (57.7) | |
Non-screen detected | 805 (66.4) | 601 (74.7) | 440 (75.0) | 119 (71.7) | |
Charlson score | <0.001 | ||||
0 | 1056 (87.1) | 754 (71.4) | 582 (70.5) | 124 (71.7) | |
1+ | 156 (12.9) | 82 (52.6) | 53 (53.5) | 25 (55.6) | |
Diagnosis year | 0.003 | ||||
1999-2002 | 269 (22.2) | 201 (74.7) | 160 (73.7) | 31 (79.5) | |
2003-2006 | 374 (30.9) | 267 (71.4) | 216 (72.5) | 38 (66.7) | |
2007-2009 | 292 (24.1) | 183 (62.7) | 128 (60.7) | 39 (65.0) | |
2010-2012 | 277 (22.9) | 185 (66.8) | 131 (66.2) | 41 (66.1) | |
Grade | <0.001 | ||||
Grade I | 168 (13.9) | 70 (41.7) | 62 (43.4) | 6 (33.3) | |
Grade II | 617 (50.9) | 409 (66.3) | 305 (66.0) | 83 (66.9) | |
Grade III | 395 (32.6) | 340 (86.1) | 254 (85.8) | 57 (83.8) | |
Missing | 32 (2.6) | 17 (53.1) | 14 (60.9) | 3 (37.5) | |
ER/PR status | <0.001 | ||||
ER &/or PR + | 926 (76.4) | 598 (64.6) | 457 (64.3) | 103 (63.6) | |
ER & PR - | 276 (22.8) | 233 (84.4) | 173 (84.4) | 46 (83.6) | |
Missing | 10 (0.8) | 5 (50.0) | 5 (62.5) | 0 | |
T stage | <0.001 | ||||
T1 | 368 (30.4) | 234 (63.6) | 196 (62,6) | 29 (69.0) | |
T2 | 692 (57.1) | 484 (69.9) | 364 (71.4) | 83 (62.4) | |
T3 | 83 (6.8) | 64 (77.1) | 40 (74.1) | 19 (82.6) | |
T4 | 62 (5.1) | 50 (80.6) | 31 (77.5) | 18 (90.0) | |
Missing | 7 (0.6) | 4 (55.6) | 4 (55.6) | 0 | |
N stage | <0.001 | ||||
0 | 406 (33.5) | 223 (54.9) | 165 (54.6) | 37 (50.0) | |
1 | 537 (44.3) | 381 (70.9) | 291 (70.0) | 72 (74.2) | |
2+ | 269 (22.2) | 232 (86.2) | 179 (86.9) | 40 (85.1) | |
LVI | <0.001 | ||||
Negative | 783 (64.6) | 484 (61.8) | 362 (61.0) | 88 (62.0) | |
Positive | 429 (35.4) | 352 (82.1) | 273 (82.5) | 61 (80.3) | |
HER-2 | <0.001 | ||||
Negative | 658 (54.3) | 414 (62.9) | 314 (63.2) | 79 (60.8) | |
Equivocal | 48 (4.0) | 25 (52.1) | 17 (48.6) | 6 (66.7) | |
Positive | 219 (18.1) | 188 (85.8) | 134 (86.5) | 37 (80.4) | |
Missing | 287 (23.7) | 209 (72.8) | 170 (71.7) | 27 (81.8) | |